Novartis Didn't Know JAK, Until Now (at Motley Fool)
is giving the company a wad of cash to license its most promising drug candidate. The drug, INCB18424, is an inhibitor of JAK1 and JAK2, two proteins involved in signaling in the cell with inflammatory diseases and cancer. The...


